Nkarta, Inc. (NASDAQ:NKTX) Shares Purchased by Wasatch Advisors LP

Wasatch Advisors LP lifted its holdings in Nkarta, Inc. (NASDAQ:NKTX) by 31.7% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,834,680 shares of the company’s stock after purchasing an additional 442,125 shares during the quarter. Wasatch Advisors LP’s holdings in Nkarta were worth $8,293,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in shares of Nkarta by 26.0% in the 1st quarter. Vanguard Group Inc. now owns 1,966,271 shares of the company’s stock worth $21,255,000 after purchasing an additional 405,753 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Nkarta by 12.0% in the 2nd quarter. Renaissance Technologies LLC now owns 912,872 shares of the company’s stock worth $5,395,000 after purchasing an additional 98,000 shares in the last quarter. Marshall Wace LLP lifted its position in Nkarta by 136.7% during the 2nd quarter. Marshall Wace LLP now owns 439,973 shares of the company’s stock worth $2,600,000 after acquiring an additional 254,104 shares during the period. Acadian Asset Management LLC lifted its position in Nkarta by 11,164.3% during the 2nd quarter. Acadian Asset Management LLC now owns 303,461 shares of the company’s stock worth $1,792,000 after acquiring an additional 300,767 shares during the period. Finally, Cubist Systematic Strategies LLC acquired a new stake in Nkarta during the 2nd quarter worth about $1,489,000. Institutional investors and hedge funds own 80.54% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on NKTX shares. RODMAN&RENSHAW raised Nkarta to a “strong-buy” rating in a research report on Wednesday, October 9th. Mizuho lowered their price target on Nkarta from $20.00 to $16.00 and set an “outperform” rating for the company in a research report on Thursday, November 21st. Raymond James raised Nkarta from an “outperform” rating to a “strong-buy” rating and set a $16.00 price target for the company in a research report on Wednesday, August 14th. Rodman & Renshaw started coverage on Nkarta in a research report on Wednesday, October 9th. They set a “buy” rating and a $14.00 price target for the company. Finally, HC Wainwright lowered their price target on Nkarta from $22.00 to $18.00 and set a “buy” rating for the company in a research report on Monday, November 11th. Five research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $15.00.

Nkarta Stock Performance

NASDAQ NKTX opened at $2.87 on Friday. The stock has a 50-day simple moving average of $3.54 and a two-hundred day simple moving average of $5.11. The firm has a market capitalization of $202.53 million, a P/E ratio of -1.53 and a beta of 0.86. Nkarta, Inc. has a fifty-two week low of $2.38 and a fifty-two week high of $16.24.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.